Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Carcinoma, Hepatocellular 54Stomach Neoplasms 42Carcinoma, Non-Small-Cell Lung 31Colorectal Neoplasms 21Esophageal Squamous Cell Carcinoma 15Nasopharyngeal Carcinoma 11Lung Neoplasms 11Rectal Neoplasms 10Esophageal Neoplasms 9Pancreatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 5Liver Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Colonic Neoplasms 3Carcinoma 3Breast Neoplasms 3Turcot syndrome 2Thyroid Neoplasms 2Spinocerebellar Degenerations 2Sarcoma 2Nonsquamous Non-Small Cell Lung Cancer 2

Interventions

Etoposide 7pegaspargase 5Methylprednisolone 4Dexamethasone 4Cyclophosphamide 3Alemtuzumab 3Gemcitabine 2Doxorubicin 2zanubrutinib 1tocilizumab 1sintilimab 1ruxolitinib 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Vincristine 1Thiotepa 1Th1-Th2 Balance 1Tacrolimus 1Rituximab 1Prednisone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methylprednisolone Hemisuccinate 1Methotrexate 1Melphalan 1Flow Cytometry 1EPOCH protocol 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphohistiocytosis, Hemophagocytic × sintilimab × Clear all
NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Sun Yat-sen University

Phase 2 Unknown
37 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡